The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management

Summary & key facts

This review says tetrahydrocannabivarin (THCV) is a non-psychoactive compound from Cannabis that affects cannabinoid receptors in ways different from THC. Lab and animal studies found THCV can lower appetite, improve how the body handles glucose and insulin, reduce fat build-up in liver and fat cells, and boost cell energy activity. Early human trials hint that THCV can change appetite and blood sugar control, but bigger and better clinical studies are needed to confirm safety and benefit.

Key facts:

• THCV is described as non-psychoactive and comes from Cannabis sativa.
• THCV acts as an antagonist at the CB1 receptor and as a partial agonist at the CB2 receptor, according to the review.
• Preclinical (cell and animal) studies reported that THCV improved insulin sensitivity and promoted glucose uptake in metabolic tissues.
• Cell and animal research found THCV reduced lipid accumulation in adipocytes and hepatocytes and improved mitochondrial activity in those cells.
• Animal models showed THCV could suppress appetite and help prevent hepatosteatosis (fatty liver) and improve metabolic homeostasis.
• Preliminary human trials reported that THCV may affect appetite and glycemic (blood sugar) control, but the review states larger-scale clinical trials are needed to confirm efficacy and safety.
• The review notes limitations and calls for more work on optimal formulations, well-designed clinical studies, and regulatory issues before THCV’s clinical role is clear.

Abstract

Disorders of the metabolism, including obesity and type 2 diabetes, represent significant global health challenges due to their rising prevalence and associated complications. Despite existing therapeutic strategies, including lifestyle interventions, pharmacological treatments, and surgical options, limitations such as poor adherence, side effects, and accessibility issues call attention to the need for novel solutions. Tetrahydrocannabivarin (THCV), a non-psychoactive cannabinoid derived from Cannabis sativa, has emerged as a promising agent to manage metabolic disorders. Unlike tetrahydrocannabinol (THC), THCV exhibits an antagonistic function on the CB1 receptor and a partial agonist function on the CB2 receptor, thus enabling appetite suppression, enhanced glucose regulation, and increased energy expenditure. Preclinical studies demonstrated that THCV improves insulin sensitivity, promotes glucose uptake, and restores insulin signaling in metabolic tissues. Additionally, THCV reduces lipid accumulation and improves the mitochondrial activity in adipocytes and hepatocytes, shown through both cell-based and animal research. Animal models further revealed THCV's potential to suppress appetite, prevent hepatosteatosis, and improve metabolic homeostasis. Preliminary human trials support these findings, thereby showing that THCV may modulate appetite and glycemic control, though larger-scale studies are necessary to confirm its clinical efficacy and safety. THCV's unique pharmacological profile positions it as a possible therapeutic candidate to address the multifaceted challenges of obesity and diabetes. Continued research should concentrate on optimizing formulations, undertaking well-designed clinical studies, and addressing regulatory hurdles to unlock its full potential.

Topics

Cannabis and Cannabinoid Research Diet, Metabolism, and Disease Liver Disease Diagnosis and Treatment

Categories

Endocrinology, Diabetes and Metabolism Health Sciences Medicine

Tags

Cannabinoid Diabetes management Diabetes mellitus Endocrinology Internal medicine Medicine Obesity Pharmacology Receptor Type 2 diabetes Weight loss Weight management

Substances

Cannabis

Conditions & symptoms

Poor appetite or overeating